Types T-Cell Lymphomas

T-cell lymphomas are cancers that start from mature (“peripheral”) T lymphocytes. They are uncommon compared with B-cell lymphomas and include many subtypes with different behaviors, symptoms, and treatments. Major groups include nodal T-cell lymphomas (like angioimmunoblastic and PTCL-NOS), extranodal types (intestinal, nasal NK/T), hepatosplenic T-cell lymphoma, anaplastic large cell lymphoma (ALK-positive or ALK-negative), and primary cutaneous T-cell lymphomas such as mycosis fungoides and Sézary syndrome. Modern classifications (WHO 5th edition / ICC) also group several “T-follicular helper (TFH)” lymphomas together. Cancer.gov+2PMC+2

T-cell lymphoma is a cancer of T lymphocytes, a type of white blood cell that helps your immune system fight infections. In this illness, one T-cell becomes abnormal (malignant) and copies itself many times. These cancer cells can collect in lymph nodes, skin, blood, bone marrow, the liver or spleen, and many other organs. Doctors group most of these diseases under “peripheral (mature) T-cell and NK-cell lymphomas,” while a related cancer from very early T-cells is called T-lymphoblastic lymphoma. Together, T-cell lymphomas make up a minority of non-Hodgkin lymphomas but include many distinct subtypes that behave differently and need expert diagnosis. Wiley Online Library+2Cancer.gov+2

Modern classifications (WHO 5th edition and the International Consensus Classification) refined names and groupings based on cell-of-origin, microscopic features, and gene changes. One big update is the family of “nodal T-follicular helper (TFH) cell lymphomas,” which includes angioimmunoblastic T-cell lymphoma and closely related forms. These updates matter because they influence which tests are done and which treatments fit best. PMC+1

Cutaneous T-cell lymphomas (CTCLs), such as mycosis fungoides and Sézary syndrome, mainly start in the skin and can look like eczema or psoriasis for years before the diagnosis is clear. CTCLs are still T-cell lymphomas, but they are managed and staged a bit differently from other T-cell lymphomas. NCCN

Doctors now often organize T-cell lymphomas into: nodal TFH lymphomas (includes angioimmunoblastic), PTCL-NOS, ALK-positive or ALK-negative anaplastic large cell lymphoma, extranodal NK/T-cell lymphoma (usually nasal), enteropathy-associated and monomorphic epitheliotropic intestinal T-cell lymphomas, hepatosplenic T-cell lymphoma, adult T-cell leukemia/lymphoma (HTLV-1–associated), and primary cutaneous T-cell lymphomas (MF/SS and others). Knowing the subtype guides testing and treatment. Cancer.gov+1

---

Other names you may hear

You might see these alternate names on reports or websites. They are all part of the T-cell/NK-cell lymphoma family:

• Peripheral T-cell lymphoma (PTCL) or mature T-cell lymphoma (umbrella terms for many subtypes).

• Nodal TFH-cell lymphomas, including angioimmunoblastic T-cell lymphoma (AITL), TFH-type PTCL (follicular type), and nodal PTCL with TFH phenotype.

• Anaplastic large cell lymphoma (ALCL): ALK-positive, ALK-negative, or primary cutaneous ALCL.

• Extranodal NK/T-cell lymphoma, nasal type (linked to EBV).

• Enteropathy-associated T-cell lymphoma (EATL) and monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL).

• Hepatosplenic T-cell lymphoma (HSTCL).

• Subcutaneous panniculitis-like T-cell lymphoma.

• Adult T-cell leukemia/lymphoma (ATLL) (linked to HTLV-1).

• T-lymphoblastic lymphoma (T-LBL) (from very early T-cells).

• Cutaneous T-cell lymphomas: mycosis fungoides and Sézary syndrome. Wiley Online Library+2PMC+2

---

Types

1. Nodal TFH-cell lymphomas (including AITL). These start in lymph nodes and arise from specialized “helper” T-cells that live in follicles. They often cause generalized lymph node swelling, rashes, fevers, and high antibody-producing B-cells in the background; EBV-positive B-cells are common. PMC
2. Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). A “catch-all” for mature T-cell lymphomas that don’t fit other categories. It varies a lot from person to person, so treatment is individualized. Wiley Online Library
3. Anaplastic large cell lymphoma (ALCL). Comes in ALK-positive and ALK-negative systemic forms, plus a skin-limited (primary cutaneous) form. Many cases strongly express the CD30 marker, which can guide targeted therapy. Wiley Online Library
4. Extranodal NK/T-cell lymphoma, nasal type. Typically affects the nose and sinuses, can cause nosebleeds and blockage, and is associated with Epstein–Barr virus (EBV). More common in parts of Asia and Latin America. ScienceDirect
5. Intestinal T-cell lymphomas: EATL and MEITL. EATL is linked to celiac disease; MEITL is a distinct entity often not linked to celiac disease. Both can cause abdominal pain, weight loss, and bowel problems. PMC
6. Hepatosplenic T-cell lymphoma (HSTCL). Rare and aggressive; often in young males and sometimes in people with inflammatory bowel disease who’ve taken certain immunosuppressive drugs. PMC+1
7. T-lymphoblastic lymphoma (T-LBL). An aggressive cancer from very early T-cells; often involves the chest (thymus) in teens and young adults and is treated like acute lymphoblastic leukemia. NewYork-Presbyterian
8. Cutaneous T-cell lymphomas (CTCL). Mycosis fungoides (patches/plaques/tumors on the skin) and Sézary syndrome (diffuse redness with malignant T-cells in blood). NCCN

---

Causes and risk factors

We still don’t know one single “cause.” Most risks are associations that raise chances for some subtypes.

1. HTLV-1 infection. This retrovirus can cause adult T-cell leukemia/lymphoma after many years. It is endemic in parts of Japan, the Caribbean, and Africa. NCBI

2. EBV (Epstein–Barr virus). EBV drives NK/T-cell lymphoma, nasal type, and can be present in the background of TFH-type lymphomas. ScienceDirect+1

3. Celiac disease (untreated or refractory). Strongly linked to EATL, an intestinal T-cell lymphoma. Lifelong gluten control lowers ongoing gut inflammation. PMC

4. Immunosuppression from medicines. Certain drug combinations for inflammatory bowel disease (thiopurines ± anti-TNF) are linked to rare HSTCL, especially in young men. CGH Journal+1

5. Inflammatory bowel disease itself. Chronic immune activation plus immunosuppressive therapy may add risk for HSTCL. PMC

6. HIV infection (immune deficiency). HIV greatly raises overall lymphoma risk; T/NK lymphomas remain uncommon but do occur. Lippincott Journals+1

7. Solid-organ or stem-cell transplant. Post-transplant lymphoproliferative disorders are usually B-cell, but T-cell lymphomas, including CTCL, can develop rarely under chronic immunosuppression. PMC+1

8. Breast implants (textured). Rarely, textured implants can lead to breast-implant-associated ALCL (BIA-ALCL), a T-cell lymphoma in the capsule around the implant. U.S. Food and Drug Administration+1

9. Psoriasis and chronic skin inflammation. Severe or long-standing psoriasis is associated with a higher risk of CTCL; prior systemic immunosuppressants may contribute. Oxford Academic+1

10. Geography/ethnicity. NK/T-cell lymphoma is more frequent in East Asia and Latin America; ATLL clusters where HTLV-1 is common. ScienceDirect+1

11. Male sex (subtype-specific). HSTCL shows a strong male predominance; several PTCLs are more common in men. PMC

12. Older age (for many PTCLs). Many mature T-cell lymphomas occur in older adults, though some (like HSTCL, T-LBL) skew younger. jadpro

13. Family history of lymphoma. Having a close relative with lymphoma slightly raises individual risk; this is nonspecific but recognized. Mayo Clinic

14. Chemical exposures. Occupational pesticide/fertilizer exposure and smoking have been reported in PTCL-NOS cohorts; evidence is suggestive. jadpro

15. Co-infections and immune dysregulation. EBV and HTLV-1 coinfections in immunodeficiency states are linked to some T/NK lymphomas. jorgejcastillo.com

16. Autoimmunity beyond celiac disease. Long-term immune stimulation (e.g., some autoimmune skin diseases) overlaps with later CTCL in a minority. Oxford Academic

17. Prior long-term cyclosporine in psoriasis. Individual reports link long exposure with later ATLL or CTCL; the absolute risk is low. Medical Journals

18. Chronic gluten exposure in celiac disease. Persistent gluten intake maintains gut inflammation and keeps EATL risk elevated. PMC

19. Region-specific viral patterns. Where EBV or HTLV-1 are common, T/NK lymphomas are relatively more frequent. ScienceDirect+1

20. Breast implant texture and time since placement. BIA-ALCL risk is highest with certain textured devices and typically appears years after surgery. U.S. Food and Drug Administration+1

---

Common symptoms

1. Painless, enlarged lymph nodes. Swelling in the neck, armpits, or groin that doesn’t go away is a classic sign. Cancer.gov

2. “B” symptoms. Unexplained fevers, drenching night sweats, and weight loss can signal active disease. Cancer.gov

3. Tiredness and low energy. Anemia, inflammation, or the cancer itself can cause fatigue. Cancer.gov

4. Skin patches, plaques, or tumors. CTCL can mimic eczema or psoriasis but tends to persist and slowly worsen. NCCN

5. Itching (pruritus). Itching can be intense in CTCL and also occurs in other lymphomas. NCCN

6. Red, peeling or thick skin (erythroderma). In Sézary syndrome, widespread redness and scaling reflect blood involvement. NCCN

7. Enlarged spleen or liver. Fullness or pain under the ribs may reflect organ enlargement. Cancer.gov

8. Abdominal pain, diarrhea, or weight loss. EATL/MEITL often start with gut symptoms. PMC

9. Nasal blockage or nosebleeds. NK/T-cell lymphoma in the nose and sinuses often presents this way. ScienceDirect

10. Chest pressure or cough. A mediastinal mass or enlarged nodes can cause breathing symptoms. Cancer.gov

11. Frequent infections. Abnormal immune function and low white counts can increase infection risk. Cancer.gov

12. Easy bruising or bleeding. Low platelets from marrow involvement may lead to bruising or nosebleeds. Cancer.gov

13. Bone or back pain. Rarely, marrow or bone involvement causes pain. Cancer.gov

14. Swollen tonsils or a new oral/nasal mass. NKTCL or nodal disease can present in the head and neck. ScienceDirect

15. General “not right” feeling. Appetite loss, malaise, and low-grade fevers are common nonspecific signs. Cancer.gov

---

Diagnostic tests

A) Physical examination

1) Full lymph node exam. The doctor maps which nodes are enlarged, their size, and tenderness. Pattern (localized vs widespread) guides staging and next tests. Cancer.gov

2) Skin inspection. Rashes, patches, plaques, and tumors suggest CTCL; distribution and duration steer biopsy sites. NCCN

3) Organ check (abdomen, liver, spleen). Feeling for organ enlargement helps stage and choose imaging. Cancer.gov

4) Symptom review for “B symptoms.” Fever, drenching sweats, and weight loss are recorded because they affect stage and prognosis. Cancer.gov

B) “Manual” bedside tests and simple tools

5) Lymph-node palpation mapping. Careful measurement over time shows growth or response to treatment and helps select the best node for biopsy. (General practice)

6) Basic head & neck look (mirror/anterior rhinoscopy). In suspected NK/T disease, a simple office look can spot masses that need urgent ENT endoscopy and biopsy. ScienceDirect

7) Dermoscopy/diascopy for lesions. A handheld skin scope can highlight features that target the most informative biopsy site in CTCL. PMC

C) Laboratory & pathology

8) Excisional lymph-node or tissue biopsy (the key test). Removing an entire node (or a deep core of tissue) lets the pathologist confirm lymphoma, define the exact subtype, and run crucial markers. PMC

9) Immunohistochemistry (IHC) and flow cytometry. These tests show T-cell markers (like CD3, CD4/CD8) and other clues (e.g., CD30), and help separate T-cell from B-cell diseases. ARUP Consult

10) T-cell receptor (TCR) gene rearrangement (“clonality”). PCR/NGS looks for a dominant T-cell clone in skin, node, or blood—supporting the diagnosis and sometimes prognosis. Results must be interpreted with care. JAMA Network+1

11) Broad blood panel (CBC with differential). Checks anemia, low platelets, or abnormal lymphocytes; guides urgency and staging. Cancer.gov

12) Chemistry tests (kidney/liver) and LDH. LDH often tracks tumor activity; organ tests are important for both staging and safe treatment. Cancer.gov

13) Viral studies as appropriate. EBV DNA/EBER in tissue for NK/T lymphoma; HTLV-1 testing if ATLL is possible; HIV and hepatitis screening help both diagnosis and safe therapy. ScienceDirect+1

14) Bone marrow biopsy/aspirate. Looks for spread to marrow, refines stage, and can provide material for flow/TCR studies. Today, PET-CT sometimes reduces the need, but marrow biopsy is still used. PMC+1

15) Molecular testing for mutations (entity-specific). For example, TFH-type lymphomas often harbor TET2, DNMT3A, and RHOA mutations; results can support classification and clinical trials. PMC

D) Electrodiagnostic tests

16) Electrocardiogram (ECG). Not diagnostic of lymphoma itself, but important to establish a safe baseline before certain treatments and to evaluate chest symptoms. (Standard oncology practice references embed this in workup algorithms.) MD Anderson Cancer Center

17) EEG or EMG/nerve conduction (when indicated). If there are seizures or neuropathy suggesting nervous-system involvement, these tests help define the problem and guide imaging/biopsy. (Clinical-context use)

E) Imaging & endoscopy

18) PET-CT (FDG-PET). The best single test to map active lymphoma throughout the body, guide biopsies, and assess response during/after treatment in many PTCLs. PMC

19) Contrast CT of neck/chest/abdomen/pelvis. Defines enlarged nodes and organ disease; used with or without PET depending on local practice and subtype. Cancer.gov

20) MRI or targeted endoscopy when site-specific symptoms exist. MRI is helpful in brain/spine or nasopharynx; GI endoscopy is used for suspected intestinal T-cell lymphoma to see and biopsy lesions.

Non-pharmacological treatments

1. Active surveillance (selected early CTCL). Careful monitoring when disease is indolent avoids overtreatment; escalate if lesions progress.

2. Skin care & itch control. Emollients, gentle cleansers, and trigger avoidance improve barrier and reduce pruritus burden.

3. NB-UVB phototherapy. Narrowband UVB treats patch/plaque MF by inducing T-cell apoptosis in skin.

4. PUVA photochemotherapy. Psoralen + UVA penetrates deeper plaques and tumors; induces apoptosis of malignant T cells.

5. Total skin electron-beam therapy (TSEBT). Low- or standard-dose electron beams treat widespread skin disease with limited depth.

6. Local radiotherapy (electron/photon). Highly radiosensitive lesions (skin or nodes) can be controlled or palliated.

7. Extracorporeal photopheresis (ECP). Leukapheresis + UVA/psoralen modulates immune cells; useful in Sézary and erythrodermic MF.

8. Exercise therapy. Structured aerobic + resistance programs improve fatigue, function, and quality of life during/after treatment.

9. Oncology nutrition support. Individualized energy/protein goals (often ~25–30 kcal/kg and ≥1.2 g protein/kg/day) support weight and healing.

10. Psychological support/CBT. Reduces distress, improves coping with chronic courses like CTCL.

11. Sun protection and wound care. Protects fragile treated skin; careful dressing of ulcerated tumors lowers infection risk.

12. Smoking cessation. Improves overall outcomes and surgical/radiation tolerance.

13. Vaccination planning. Inactivated vaccines (e.g., influenza) are advised; live vaccines avoided during immunosuppression.

14. Infection-prevention bundles. Hand hygiene, central-line care, and clinic protocols cut infection risk.

15. Physical therapy. Counters deconditioning and lymphedema; preserves mobility after intensive therapy.

16. Dermatology-led itch strategies. Wet wraps, antipruritic routines, and sleep hygiene improve comfort in MF/SS.

17. Palliative care. Early integration relieves symptoms and supports decision-making in aggressive subtypes.

18. Sunlight timing/avoidance post-photosensitizers. Minimizes phototoxicity after PUVA/ECP sessions.

19. Support groups/education. Better self-care and adherence through patient education resources.

20. Multidisciplinary tumor board review. Ensures pathology accuracy and best-evidence care plans.

---

Drug treatments

1) Brentuximab vedotin + CHP (front-line for CD30+ PTCL).
Class: CD30-directed antibody–drug conjugate with cyclophosphamide, doxorubicin, prednisone. Dose/time: Brentuximab vedotin 1.8 mg/kg IV q3wk with CHP for 6 cycles is typical; give G-CSF prophylaxis. Purpose/mechanism: Targets CD30; MMAE payload kills malignant cells. Evidence: ECHELON-2 showed superior PFS/OS vs CHOP at 5 years. Key side effects: Neutropenia, neuropathy; avoid with bleomycin.

2) CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone).
Class: Multi-agent cytotoxic chemo. Use: Legacy standard when CD30 is low/absent or BV isn’t suitable. Notes: Cardiac monitoring needed due to anthracycline. Side effects: Myelosuppression, neuropathy, cardiotoxicity.

3) Pralatrexate.
Class: Antifolate. Dose: 30 mg/m² IV push weekly ×6 in 7-week cycles with folate/B12. Use: Relapsed/refractory PTCL. Effects: Mucositis, myelosuppression. Evidence: FDA-approved based on response rate.

4) Romidepsin.
Class: HDAC inhibitor. Dose: 14 mg/m² IV over 4 h on days 1, 8, 15 q28d. Use: Relapsed PTCL/CTCL. Mechanism: Epigenetic modulation triggering apoptosis. Effects: Cytopenias, QT effects.

5) Belinostat.
Class: HDAC inhibitor. Dose: 1,000 mg/m² IV daily days 1–5 q21d. Use: Relapsed PTCL. Effects: Myelosuppression, liver enzyme rise.

6) Vorinostat.
Class: HDAC inhibitor. Dose: 400 mg PO daily. Use: Refractory/progressive CTCL. Effects: Fatigue, diarrhea, thrombocytopenia.

7) Bexarotene.
Class: Retinoid (RXR agonist). Dose: 300 mg/m²/day PO; topical gel for lesions. Use: CTCL. Effects: Hypertriglyceridemia, hypothyroidism—monitor labs.

8) Methotrexate (low-dose).
Class: Antimetabolite. Use: CTCL (skin-directed/systemic) in selected patients. Notes: Evidence supports activity, especially earlier use; monitor liver and counts.

9) Interferon-alpha.
Class: Immunotherapy. Dose: Commonly 3–10 million units several times weekly or peg-IFN 135–180 μg weekly, individualized. Use: MF/SS alone or with phototherapy. Effects: Flu-like symptoms, cytopenias, mood changes.

10) Mogamulizumab.
Class: Anti-CCR4 antibody. Use: Relapsed MF/SS; also active in ATLL. Effects: Infusion reactions, rash; risk of severe GVHD post-allo-SCT—sequence carefully.

11) Alectinib / Crizotinib (ALK inhibitors).
Class: ALK TKIs. Use: Relapsed ALK-positive ALCL, especially when chemo fails; responses documented in adults and children. Effects: Liver enzyme rise, bradycardia, edema.

12) Lenalidomide.
Class: Immunomodulatory. Use: Relapsed PTCL (notably AITL); modest single-agent activity, sometimes combined with romidepsin. Effects: Cytopenias, rash, thrombosis risk.

13) Duvelisib (selected R/R PTCL).
Class: PI3K-δ/γ inhibitor. Use: Activity reported in trials; toxicity (infection, colitis) requires close monitoring.

14) Gemcitabine-based regimens.
Class: Cytotoxic salvage. Use: R/R PTCL or CTCL; can shrink tumors and bridge to transplant. Effects: Myelosuppression.

15) Ifosfamide/Carboplatin/Etoposide (ICE) or DHAP.
Class: Platinum-based salvage chemo. Use: Debulking before autologous transplant in chemosensitive relapse.

16) Pegylated liposomal doxorubicin (CTCL tumors).
Class: Anthracycline. Use: Tumor-stage MF; monitor heart function.

17) Chlormethine (mechlorethamine) gel.
Class: Topical cytotoxic. Use: Lesion-directed therapy in MF; combine with phototherapy/IFN.

18) Pembrolizumab/Nivolumab (selected cases).
Class: PD-1 inhibitors. Use: Activity in NK/T and some CTCL/PTCL subsets in studies; immune-related AEs.

19) Alemtuzumab (selected).
Class: Anti-CD52 antibody. Use: Highly selected refractory T-cell leukemias/lymphomas; infection risk high.

20) Clinical trials (novel CAR-T/CAR-NK/bi-specifics).
Class: Investigational cellular/targeted approaches; options evolve quickly and may offer benefit when standard therapy fails.

Safety note: Drug doses are typical references; real prescriptions are individualized. Always use institutional protocols and labels.

---

Dietary molecular supplements

1. Protein supplements (whey/ONS). Help meet ≥1.2 g/kg/day protein goals when appetite is low. Monitor if kidney disease.

2. Vitamin D (if deficient). Replete per labs to support bone/muscle; no anticancer effect proven.

3. Omega-3 (EPA/DHA). May help with weight/appetite in cancer cachexia for some; evidence mixed.

4. Soluble fiber. Helps chemo-related diarrhea (with hydration and medical care).

5. Oral rehydration solutions. Replace fluids/electrolytes during GI side effects.

6. Multivitamin (RDA-level). For patients with poor intake; avoid mega-doses.

7. Zinc (short course for mucositis if deficient). Consider only with clinician guidance.

8. Probiotics—avoid during neutropenia. Infection risk can outweigh benefit in the severely immunocompromised.

9. Folate/B12 with pralatrexate. Required to reduce mucositis and cytopenias.

10. Caffeine-free hydration + small frequent meals. Practical support for fatigue and treatment tolerance.

---

Immunity-support / regenerative / stem-cell–related drugs

1. Filgrastim (G-CSF). Stimulates neutrophil recovery after chemo; typical dosing 5 μg/kg/day SC until ANC recovery; reduces febrile neutropenia.

2. Pegfilgrastim. Long-acting G-CSF given once per chemo cycle; improves convenience and lowers neutropenia risk.

3. IVIG (intravenous immunoglobulin). For recurrent infections with hypogammaglobulinemia; individualized dosing.

4. Plerixafor (with G-CSF). Mobilizes stem cells from marrow to blood before autologous transplant collection.

5. Epoetin alfa (selected anemia). Can reduce transfusions in chemo-induced anemia when used by guideline criteria.

6. Eltrombopag/Romiplostim (selected thrombocytopenia). May be considered in specific settings; coordinate with specialist.

---

Surgeries/procedures

1. Excisional lymph node or skin biopsy. Gold standard to diagnose subtype accurately and guide treatment.
2. Central venous catheter/port placement. Provides reliable access for multi-cycle chemotherapy and blood draws.
3. Splenectomy (selected). Rarely for diagnostic uncertainty, hypersplenism, or symptomatic splenomegaly.
4. Autologous stem-cell transplant (ASCT). Consolidation in chemosensitive disease or salvage—role varies by subtype and response.
5. Allogeneic stem-cell transplant (allo-SCT). Potentially curative graft-versus-lymphoma effect in high-risk or relapsed cases, balanced against GVHD risks.

---

Prevention tips

1. Follow hand hygiene and clinic infection-control steps every visit.

2. Keep vaccinations up-to-date with inactivated vaccines (timed around therapy); avoid live vaccines when immunosuppressed.

3. Use safe food handling; strict “neutropenic diets” aren’t evidence-based—focus on hygiene and fully cooked foods during neutropenia.

4. Seek prompt care for fever ≥38.0 °C or chills.

5. Protect treated skin from sun and trauma; follow wound-care guidance.

6. Maintain exercise as tolerated to reduce fatigue and preserve function.

7. Manage heart risks before anthracyclines: BP, diabetes, lipids, and baseline echo when indicated.

8. Keep an updated medication list to avoid interactions.

9. Plan dental care and oral hygiene to lower infection risk.

10. Discuss travel/food/water safety if counts are low or you’re on immunosuppressive drugs.

---

When to see a doctor urgently

Contact your cancer team now for fever, shaking chills, shortness of breath, new chest pain, confusion, severe headache, uncontrolled vomiting/diarrhea, rapidly growing lumps, heavy bleeding/bruising, severe rash/peeling skin, jaundice, or any new neurologic symptoms. These can signal infection, disease progression, or treatment complications that need immediate care.

---

What to eat and what to avoid

1. Aim for enough calories and protein (often ~25–30 kcal/kg/day and ≥1.2 g/kg/day protein) using small, frequent meals and oral nutrition shakes if needed.
2. Hydrate regularly (water, broths, oral rehydration) to support kidneys and prevent dizziness.
3. During neutropenia, avoid raw/undercooked meat, fish, eggs; unpasteurized dairy/juices; salad bars/buffets. Wash and peel produce; prefer cooked options.
4. Food safety over fear: strong evidence supports safe handling rather than blanket “neutropenic diets.”
5. Limit alcohol; avoid if on hepatotoxic drugs (e.g., methotrexate, bexarotene can affect liver/lipids/thyroid).
6. Be cautious with supplements and herbals (e.g., high-dose antioxidants, St John’s wort); review with your team.
7. Use gentle foods if mucositis/diarrhea (soft, low-acid, lactose-free if needed).
8. Include omega-3-rich foods (fish, flax) if tolerated; they may help appetite/weight in some.
9. Maintain fiber (mainly soluble) for bowel regularity; adjust during flares.
10. Ask for a dietitian referral for a personalized plan.

---

FAQs

1) Is T-cell lymphoma curable?
Some subtypes (e.g., ALK-positive ALCL) can be cured with modern therapy; others are harder to cure and may need transplant or long-term control strategies.

2) What is the first-line treatment for many CD30-positive PTCLs?
Brentuximab vedotin plus CHP (A+CHP) improved survival over CHOP in ECHELON-2 and is widely used when CD30 is expressed.

3) Do all patients need PET-CT?
PET-CT is commonly used for baseline staging and response in many PTCLs, alongside CT and clinical exam.

4) Are there targeted pills for ALK-positive ALCL?
Yes—ALK inhibitors like alectinib or crizotinib show activity in relapsed disease, especially when standard chemo has failed.

5) What is TFH lymphoma?
It’s a group (including angioimmunoblastic) derived from T-follicular helper cells with characteristic mutations (e.g., TET2/RHOA).

6) Is phototherapy safe?
NB-UVB and PUVA are standard skin-directed therapies for MF when used under specialist protocols.

7) What is ECP?
Extracorporeal photopheresis treats circulating malignant T cells (especially in Sézary) and can improve skin and blood disease.

8) Do I need a heart test before chemo?
Before anthracyclines, guidelines recommend baseline cardiac assessment (ECG, echocardiogram based on risk).

9) Are neutropenic diets required?
Evidence does not support strict avoidance lists; focus on safe food handling and fully cooked foods during neutropenia.

10) When is transplant used?
ASCT may consolidate remission; allo-SCT offers graft-versus-lymphoma effects in high-risk or relapsed disease.

11) Are immunotherapy drugs used?
Checkpoint inhibitors and targeted antibodies (e.g., mogamulizumab) are used in selected subtypes/lines.

12) What if treatment stops working?
Multiple active options exist (HDAC inhibitors, pralatrexate, lenalidomide, gemcitabine regimens), and clinical trials are important.

13) Will diet cure lymphoma?
No diet or supplement cures T-cell lymphoma; nutrition supports strength and treatment tolerance.

14) What labs matter during therapy?
CBC, chemistry, LDH, and disease-specific tests (e.g., Sézary counts) guide safety and response.

15) Who should be on my care team?
Hematology/oncology, dermatology (for CTCL), radiation oncology, pathology, cardiology (as needed), nursing, dietetics, and palliative care.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 17, 2025.